Titan Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Titan Pharmaceuticals

17/05/2021 23:13

* Titan Pharmaceuticals Inc  TTNP.OQ  reported a quarterly
adjusted loss of 28 cents​​ per share for the quarter ended
in March. The lone analyst forecast for the quarter was for a
loss of 85 cents per share.
* Revenue fell 49% to $682.00 thousand from a year ago; 
analysts expected zero. 
* Titan Pharmaceuticals Inc's reported EPS for the quarter was a
loss of 28 cents​.
* In the last 30 days there have been no negative revisions of
earnings estimates 
* Titan Pharmaceuticals Inc shares had fallen by 22.1% this
quarter and lost 29.5% so far this year.
* The company reported a quarterly loss of $2.64 million.
* Wall Street's median 12-month price target for Titan
Pharmaceuticals Inc is $7.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 17 at 10:13 p.m. GMT.
​All figures in US dollars